INTRODUCTION
Growth parameters are routinely measured in general pediatrics, with the goal of identifying children with abnormalities in growth and stature. Short stature is defined as a height less than 2 standard deviations (SDs) below the mean of the "normal" population, while tall stature is defined as a height greater than 2 SDs above the mean of the normal population. Both single growth measurements and the pattern of growth over time (growth velocity) are useful in identifying children with abnormal stature. The growth velocity changes over time, with relatively rapid growth in infancy and early childhood, followed by slower growth (approximately 5 cm per year) in later childhood and then rapid growth again during puberty. There is a range of pubertal peak growth velocities of around 7 to 12 cm per year and 6 to 10.5 cm per year in boys and girls, respectively, representing approximately the 3rd to 97th percentiles. The timing of peak growth velocity varies with the age of puberty onset and frequently reflects familial pubertal and growth patterns. Overall, it is thought that genetics may explain more than 80% of the variation in heights within a population. When children exhibit abnormal growth patterns, it is critical that pediatricians perform a proper diagnostic evaluation, which may ultimately include referral to a pediatric endocrinology subspecialist.
Measurement of Growth
The identification of physiological and pathologic growth patterns relies on accurate measurements of length and height. (1) In children under the age of 2 years, measurement of supine length is preferred. In children older than age 3 years, AUTHOR DISCLOSURE Dr Braun has disclosed that she receives grant funding from National Institutes of Health T32HD052961-10. Dr Marino has disclosed no financial relationships relevant to this article. This commentary does not contain a discussion of an unapproved/investigative use of a commercial product/device. standing height measurement is the favored method. For children between ages 2 and 3 years, it is best to measure both supine length and standing height and compare the two measurements. To measure supine length, the child should be on a firm surface, with a fixed headboard and mobile footboard. Measurement of height is ideally performed with a stadiometer, with the child's shoes and headwear removed and the child's head, shoulders, buttocks, and heels touching the wall. The "Frankfurt plane," the anatomic line that connects the outer canthus of the eye and the external auditory meatus, should be perpendicular to the board or the wall for length and height measurements, respectively. Measurements should be obtained to the nearest tenth of a centimeter and, if possible, measured in triplicate and averaged. This is ideally performed by a well-trained and consistent staff member. Head circumference should be measured with a measuring tape around the forehead above the eyebrows, over the ears, and around the most prominent part of the back of the head. Weight measurements should be obtained without shoes and with minimal clothing by using a well-calibrated scale. Height velocity can be computed at a minimum interval of 3 months between measurements; however, 1-year intervals are ideal, given seasonal variations. Measurements should be plotted on standardized growth charts. The US Centers for Disease Control and Prevention (CDC) growth charts, developed by the National Center for Health Statistics, were initially published in 1977 and have been updated periodically, most recently in 2000. The data collected for the initial 1977 growth charts are mostly from the Fels Longitudinal Growth Study, with the caveat that the Fels cohort was predominantly children of European ancestry who were formula fed and middle class, from a single community. The 2000 update contains information collected from 5 cross-sectional nationally representative surveys (National Health Examination Survey, or NHES, II and III; and National Health and Nutrition Examination Survey, or NHANES, I, II, and III). In response to the limitations of the 1977 growth standards, the World Health Organization formed the Multicentre Growth Reference Study and collected growth information from healthy children in 6 different countries, with a key distinction being the use of breastfed children as the standard model for growth and development. The American Academy of Pediatrics and the CDC both recommend use of the 2006 World Health Organization growth charts for children between birth and age 2 years and the 2000 CDC standard growth charts for children aged 2 to 20 years. (2) By entering growth measurement inputs into both growth charts, medical providers can obtain growth percentiles and z-scores (this process is automated in many electronic health record systems). In addition to standard growth charts, a number of disease-specific growth charts are also available for disorders with atypical growth patterns, such as Turner syndrome, Down syndrome, and Noonan syndrome.
ABBREVIATIONS
Although length and height measurements among healthy children have a wide distribution, height velocities are relatively uniform. A diagnostic evaluation is therefore warranted if a child is "falling off" the height percentile or crossing two major percentile lines between age 2 years and the onset of puberty.
Midparental Height
An individual's adult height is strongly correlated to his or her familial height. The midparental height calculation can be used to estimate a child's genetic target range height. If parents are available, it is preferable to directly measure parents' height rather than relying on self-reported values, which may be inaccurate. The caveat with estimating midparental "target height" is that inheritance patterns of stature are complex, as partly evidenced by marked height variations among healthy siblings in the same family. Further, it is worth noting that an abnormally short or tall child from parents with similar stature should not necessarily be declined further evaluation, since the child and parent(s) may possess the same genetic mutation. The midparental height is calculated as follows:
½Father's heightðcmÞ À 13 cm þ Mother's heightðcmÞ 2
Boys : ½Father's heightðcmÞ þ Mother's heightðcmÞ þ 13 cm 2
Bone Age
Skeletal maturation occurs in a predictable pattern in healthy children. An assessment of skeletal maturation can be performed with a simple radiograph of the left hand, which can be used to determine bone age. This radiograph is compared to age-and sex-matched published standards to determine a child's bone age, although this should be performed by an individual with experience in interpreting bone age radiographs. The comparison of skeletal age to chronological age is often helpful in the diagnostic evaluation of abnormal stature. By using standard references, a child's bone age and current height can also be used to estimate an adult's height, with the caveat that many other variables (including the tempo of puberty and other comorbid medical conditions) may affect the true adult height. The bone age is usually not reliable in children under the age of 5 years.
CONDITIONS ASSOCIATED WITH SHORT STATURE
Idiopathic or familial short stature and constitutional growth delay are relatively common causes of short stature, while true endocrine disorders are comparatively rare, accounting for as few as 5% of short stature cases. (3) Of note, malnutrition is a major cause of short stature worldwide.
Constitutional Delay of Growth and Puberty
Constitutional delay of growth and puberty (CDGP) is a growth pattern characterized by a normal size at birth and subsequent slowing of height velocity in the first 3 to 5 years of age. Individuals then maintain a prepubertal growth velocity during the expected time of pubertal growth spurt, resulting in a markedly decreased height percentile (can be below the 5th percentile), especially in early adolescence ( Fig  1A) . The hallmark in diagnosis is a delayed bone age finding.
Family history often reveals a parent or other relatives who reportedly underwent puberty late, so-called late bloomers. Individuals with CDGP require close monitoring of growth and pubertal advancement. Psychosocial distress resulting from short stature is common-this is particularly prevalent in boys, whose height discrepancy from peers is marked as peers enter puberty, and can ultimately lead to a decline in school performance. (4) These individuals may benefit from a consultation with a pediatric endocrinologist for possible hormonal therapy to initiate pubertal changes. Individuals with CDGP undergo complete catchup growth (with or without hormonal intervention) and achieve an adult height that is within range for their genetic potential.
Familial Short Stature
Familial short stature (FSS) is considered a normal variant, where a child's height is less than 2 SDs for his age, but the child's height is expected to still reach the calculated midparental height. These children have low normal height velocities, a normal laboratory evaluation finding, and a bone age that is in agreement with his or her chronological age. FSS is generally considered a subset of idiopathic short stature (ISS). It is worth noting that a diagnosis of FSS does not preclude underlying monogenic or polygenic alterations, as it is possible that multiple family members may carry genetic variants responsible for short stature.
Small for Gestational Age
Neonates born small for gestational age (SGA) are at risk for numerous future health issues, including short stature. SGA is defined as a birth weight and/or length less than (2) estimated 15% of children who were born SGA fail to achieve full catchup growth by age 2 years. The mechanism of growth failure in these children is not well understood, and an assessment of the growth hormone (GH) insulin-like growth factor 1 (IGF-1) axis in early life is not predictive of catchup growth. Despite the heterogeneous origins and mechanisms of poor intrauterine and extrauterine growth in this cohort, these children may benefit from therapy with recombinant human GH (rhGH).
Hypothyroidism
Children with acquired hypothyroidism may lack many of the clinical signs and symptoms that are classically present in the adult population, such as fatigue, cold intolerance, and constipation. Thyroid enlargement is often not present or is overlooked at physical examination, and one-third of children with acquired hypothyroidism receive a diagnosis in the absence of clinical symptoms. Clinically significant and progressive growth failure may be the only clinical feature of chronic acquired hypothyroidism in the pediatric population. Failure to diagnose hypothyroidism and initiate thyroid hormone replacement therapy with levothyroxine can markedly compromise adult height. The most common cause of acquired hypothyroidism in children and adults is autoimmune hypothyroidism (Hashimoto thyroiditis), with a prevalence of 1% to 2% and a 4:1 female predominance. Congenital hypothyroidism is typically diagnosed in the neonatal period, as newborn screening programs for congenital hypothyroidism are present in all 50 states and most developed countries. Screening for hypothyroidism should be performed in all children with unexplained growth failure, with or without other clinical symptoms, by measurement of thyroidstimulating hormone (TSH) and free thyroxine (T4) levels.
Glucocorticoid Excess
Chronic exposure to excess glucocorticoids has a profound effect on linear growth, with growth failure accompanied by concurrent weight gain (Fig 1B) . Cushing syndrome in children is most often exogenous as a result of glucocorticoid therapy. Endogenous Cushing syndrome is rare and can be a result of pituitary adrenocorticotropic hormone (ACTH) oversecretion (Cushing disease), a primary adrenal tumor, or, rarely, an ectopic source of ACTH or corticotropinreleasing hormone. Characteristic features of glucocorticoid excess include growth failure, truncal obesity with thin limbs, round facies, dorsocervical fat pad, decreased muscle mass, delayed puberty, striae, easy bruising, glucose intolerance, and osteoporosis, although younger children may not exhibit all of the classic stigmata. If suspected, a 24-hour urine collection for urinary free cortisol, midnight salivary cortisol, or low-dose dexamethasone suppression testing should be performed, and a referral to a pediatric endocrinologist is warranted. In patients who receive glucocorticoid therapy for treatment of a chronic underlying condition, growth should be closely monitored, and the treatment should be titrated to the minimal amount of glucocorticoid exposure required to achieve the desired treatment effect. The current data regarding effects of chronic inhaled corticosteroid on growth are controversial, with investigators in one study citing a mean 1.2-cm decrease in adult height in children treated with low-dose budesonide for a mean of 4.3 years. (5) While there may be a risk of minimally decreased adult height in this population, this risk should be weighed against the benefits of inhaled corticosteroids in preventing severe asthma exacerbations. Further, there remains a lack of definitive data on the effect of chronic inhaled corticosteroids on adult height. (6) GH Deficiency GH deficiency should be suspected in children who have a below-average growth rate, are crossing height percentiles, and have a delayed bone age finding. GH deficiency has a reported incidence of about 1 in 3,500 children. The origin of GH deficiency is frequently not determined, with 41% of cases reported as idiopathic. Among known causes, GH deficiency is attributed to intracranial lesions or treatment with radiation in 35% of cases, is congenital in 20% of cases, and occurs in the setting of syndromes with concomitant GH deficiency in 4% of cases. (7) Risk factors for GH deficiency include a history of head trauma, central nervous system (CNS) radiation, or CNS infection. Neonates with congenital GH deficiency are typically a normal size at birth; however, they may have signs suggestive of a combined pituitary hormone deficiency, such as micropenis, midline structural defects, prolonged jaundice, or hypoglycemia. Low GH values in infants at the time of hypoglycemia are diagnostic of this disorder. In children, initial laboratory testing for GH deficiency includes measurement of serum IGF-1 and IGF-1 binding protein 3 (IGF-BP3) levels. GH is secreted in a pulsatile manner; thus, single measurements are nondiagnostic for GH deficiency. If IGF-1 levels are low for age and pubertal status or if there is high clinical suspicion, a GH stimulation test should be performed.
Idiopathic Short Stature
ISS is a heterogeneous diagnosis of exclusion, which is, by definition, stature 2 SDs below the mean for age, gender, and population, with normal size for gestational age at birth; absence of chronic disease, endocrine deficiency, or chromosomal abnormalities; and normal nutritional status. (8) The bone age is variable and may be consistent with chronological age or slightly delayed or advanced. Referral to a pediatric endocrinologist is warranted to rule out other pathologic conditions and to consider GH therapy (Fig 2) .
It is worth noting that, with advances in genomic analysis, the classification of ISS may be evolving. The populationlevel height distribution is essentially gaussian, implying that 2.3% of the "normal" population lies in the left tail of the population height curve and is below À2 SDs. Through genetic and genomic analyses of this tail of the curve, both monogenic and polygenic variants associated with short stature have been identified. Thus, children previously classified as having ISS may actually harbor single-gene mutations that affect growth and the growth plate, including mutations and deletions in short-stature homeobox (SHOX), aggrecan, and natriuretic peptide receptor B (NPR2) genes, among others. In contrast to single-gene disorders, recent genome-wide association studies have yielded combinations of single-nucleotide polymorphisms that associate with short stature. For instance, Wood and colleagues identified 697 single-nucleotide polymorphisms that account for 20% of the phenotypic variance of adult height. (9) As laboratory-based studies of the genetic basis of diseases continue to progress, it is conceivable (and perhaps even likely) that children previously classified as having ISS may ultimately be found to have a clear monogenic or polygenic etiologic origin. As the cost of next-generation sequencing techniques (including whole-exome and whole-genome techniques) continues to decline, it is certainly possible that such genomic techniques may ultimately be integrated into the diagnostic evaluation for children with short stature. (10)
Chronic Illnesses
Many chronic, systemic childhood illnesses result in growth failure. Some disorders lead to growth failure by causing malnutrition, while in other cases, poor growth may be a consequence of treatment. Celiac disease, which has a prevalence of up to 1% of children, may have an insidious onset in children and lead to short stature. A Finnish cohort of 530 children with biopsy-proven celiac disease reported growth failure as the sole presenting sign in 8% of children and demonstrated that growth failure was present in 34%. (11) Growth failure is also extremely prevalent in children with Crohn disease, affecting approximately 30% of children with the disorder, although this is often reversible with optimal treatment of the gastrointestinal disease. Children with chronic kidney disease may also have growth failure as the presenting sign, which can be profound and multifactorial. rhGH therapy is beneficial in height optimization for children with chronic kidney disease. Further, childhood malignancies, pulmonary disease, and immunologic disease are all associated with growth failure, and therapies with CNS radiation, chemotherapy, and corticosteroids can further contribute to growth deceleration.
Genetic Syndromes
Numerous genetic syndromes have a described association with short stature, including chromosomal disorders, skeletal dysplasias, and other monogenic disorders. A number of these disorders are further described in Table 1 .
EVALUATION OF SHORT STATURE
In children with short stature, obtaining a through medical history is essential, paying particular attention to clues that may indicate one of the conditions mentioned previously. Birth and pregnancy history should be noted for SGA infants, as well as any complications in the neonatal period, such as hypoglycemia or prolonged jaundice (associated with GH deficiency), meconium ileus (associated with cystic fibrosis), or poor muscle tone or feeding difficulties (associated with (Table 1) , and pubertal staging. In children with growth failure, screening laboratory tests should be performed, including complete blood cell count with differential, comprehensive metabolic panel, TSH and free T4 tests, erythrocyte sedimentation rate, C-reactive protein level, celiac screening with anti-tissue transglutaminase testing, immunoglobulin A and total immunoglobulin A tests, IGF-1 test, IGF-BP3 test, and urinalysis (for identification of renal tubular acidosis). A left-hand radiograph should be obtained for assessment of bone age. Additional testing should be guided by any identified clinical signs or symptoms that may lead the practitioner to suspect a specific etiologic origin (see Table 2 for a summary of etiologic causes of short stature).
TREATMENT OF SHORT STATURE
When possible, treatment for short stature should focus on therapy for an identified underlying etiologic origin (such as hypothyroidism, glucocorticoid excess, or chronic illness). In some cases, initiation of GH therapy (under the guidance of a pediatric endocrinologist) can be considered (see Fig 2 for a listing of US Food and Drug Administrationapproved indications). In true GH deficiency, treatment with exogenous rhGH can be effective and allow many children to reach adult height within the predicted midparental height range. The data for GH therapy in other indications, such as ISS, are more varied, but overall, rhGH therapy appears to have a small but positive effect in these patients.
CONDITIONS ASSOCIATED WITH TALL STATURE
Tall stature is most commonly attributed to constitutional (or familial) tall stature or overnutrition. While tall stature can be a sign of underlying pathologic processes (as discussed herein), relatively few children will have a pathologic cause identified.
Constitutional Tall Stature
In constitutional tall stature, neonates are born with an appropriate size for gestational age. They then have an increase in growth velocity, causing them to cross length or height percentiles to greater than the 97th percentile until about the age of 4 years, when they settle into their own growth channel that parallels the growth curve. The physical examination findings are normal, with normal arm span and upper to lower segment ratio. The bone age is also typically congruent with chronological age. Family history will likely reveal a similar growth pattern in one parent and tall stature in the family. The underlying cause of constitutional tall stature is heterogeneous. GH has been implicated in some subgroups. Insulin-like growth factor 2 levels have also been shown to be higher, and this may play an important role. Genetic polymorphisms in the GH secretagogue receptor (ghrelin receptor), IGF-1, and IGF-BP3 genes and 
Hyperthyroidism
Hyperthyroidism causes accelerated linear growth with weight loss, resulting from a hypermetabolic state. The most common cause of hyperthyroidism is autoimmune Graves' disease. Subacute thyroiditis, a thyroid hormonesecreting nodule or hot nodule, and the hashitoxicosis (hyperthyroid) phase of chronic lymphocytic thyroiditis are also possible etiologic origins. Patients may present with a goiter, tachycardia, hypertension, tremor, lid lag, exophthalmos, heat intolerance and anxiety, and sleep disturbances, in addition to growth derangement. Hyperthyroidism is assessed with measurement of serum TSH, free T4, total triiodothyronine, and thyroid-stimulating immunoglobulins. A radioactive iodine-123 uptake scan or technetium-99m scan can also aid in diagnosis. Hyperthyroidism is most commonly diagnosed by means of a suppressed TSH level, with increased T4 and triiodothyronine values.
Precocious Puberty
Estrogens are responsible for the pubertal growth spurt and epiphyseal fusion in both girls and boys. Estradiol levels are low in early puberty, with a subsequent increase that leads up to peak growth velocity. In central precocious puberty, the hypothalamic-pituitary-ovarian/testicular axis is turned on prematurely, resulting in increased estrogen and testosterone production in girls and boys, respectively. This leads to outward signs of breast development in girls and testicular enlargement in boys. Growth acceleration is caused by increased estrogen production in girls and by both the aromatization of testosterone to estrogen and the smaller, direct effects of testosterone on the growth plate in boys. The effect of estrogen levels on growth is varied and depends on an individual's sensitivity to estrogen at both the level of the growth plate and the hypothalamic-GH axis, as sex steroids have an important role in increasing GH secretion during puberty. Peripheral causes of early puberty (ie, not mediated by gonadotropin-releasing hormone [GnRH] secretion) include late-onset congenital adrenal hyperplasia, McCuneAlbright syndrome, and familial male-limited precocious puberty.
Bone age assessment is markedly advanced in precocious puberty. Morning values of luteinizing hormone, folliclestimulating hormone, and estradiol in girls or testosterone in boys may be increased and consistent with central precocious puberty; however, GnRH agonist stimulation testing is frequently needed to differentiate central from peripheral puberty. Dedicated pituitary magnetic resonance imaging is performed in cases of central precocious puberty. If adrenarchal signs, such as pubic and axillary hair, are primary symptoms identified in children with advanced bone age, then ACTH stimulation testing is performed to evaluate the presence of adrenal etiologic origins. If Genetic syndrome/chromosomal abnormality See Table 1 Routine diagnostic tests include complete blood count with differential; comprehensive metabolic panel; urinalysis; thyroid-stimulating hormone and free thyroxine levels; erythrocyte sedimentation rate and C-reactive protein level; anti-tissue transglutaminase antibody testing, immunoglobulin A level, and total immunoglobulin A level; insulin-like growth factor 1 (IGF-1) testing, IGF-1 binding protein 3 testing, and bone age. Consider karyotype analysis in female patients. Additional testing should be guided by the suspected etiologic origin.
precocious puberty is left untreated, epiphyseal closure may occur early and ultimately lead to a smaller-than-expected adult height.
GH Excess
GH excess, a rare cause of tall stature in the pediatric population, can be caused by a hormone-secreting pituitary adenoma, McCune-Albright syndrome, multiple endocrine neoplasia type 1, or Carney complex. Increased GH levels cause accelerated linear growth when growth plate epiphyses are still open. Patients will also frequently have enlarged hands, feet, and jaw. In children with GH excess, IGF-1 levels will be increased for age and pubertal status. Prolactin levels may also be increased, as co-secreting adenomas are common. GH suppression testing with an oral glucose load is performed for confirmation. Dedicated pituitary magnetic resonance imaging is typically performed after the diagnosis of GH excess is confirmed, with additional diagnostic testing for McCune-Albright syndrome, multiple endocrine neoplasia type 1, or Carney complex performed as guided by associated signs and symptoms.
Familial Glucocorticoid Deficiency
Familial glucocorticoid deficiency is an ACTH-resistant state that is associated with tall stature. A detailed history and physical examination will reveal features concerning for adrenal insufficiency, including nausea, weight loss, fatigue, bronzing of the skin, and darkening of the hand creases and buccal mucosa. While it has been postulated that increased levels of ACTH, as well as ACTH receptor mutations, could contribute to additional growth, the exact mechanism for the excess growth is not known. In primary adrenal insufficiency, laboratory evaluation will reveal low morning cortisol levels with increased ACTH levels. A complete blood cell count will frequently show eosinophilia, and plasma dehydroepiandrosterone sulfate levels will also be low. Boys with an extra Y chromosome (47,XYY) typically exhibit tall stature beginning at approximately 6 years of age. Other common features of this disorder include clinodactyly, hypertelorism, macro-orchidism, and tremor. Intelligence is typically normal if the diagnosis is assigned prenatally, although there is an increased incidence of autism, attention-deficit/hyperactivity disorder, motor tics, and other behavioral problems. Finally, duplication of 15q, which contains the IGF-1 receptor gene, has also been associated with tall stature.
Abnormal Paracrine Signaling
The C-type natriuretic peptide, through binding with its cognate receptor NPR2, forms a paracrine signaling pathway that has demonstrated a role in skeletal growth. Gain of function mutations in NPR2 are inherited in an autosomal dominant fashion and have been found to cause tall stature in multiple members (across generations) within a family. Other abnormalities in paracrine signaling have also been identified, including loss of function mutations in the fibroblast growth factor receptor 3, which positively affects linear growth and leads to tall stature.
Genetic Syndromes
Sotos syndrome, or cerebral gigantism, is described as tall stature prenatally and in childhood. It is associated with advanced bone age, macrocephaly, cardiac and genitourinary abnormalities, benign and malignant tumors, brain malformations, developmental delay, and dysmorphic facial features. Deletions in the nuclear receptor binding SET-domain 1, or NSD-1, gene, which lead to loss of function, account for most cases in Japanese populations, while NSD-1 mutations occur more frequently in non-Japanese populations.
Weaver syndrome, which is caused by mutations in histone-lysine-N-methyltransferase, manifests with tall stature, characteristic facial features, intellectual disability, clinodactyly, scoliosis, and hearing loss. Growth is accelerated in both the pre-and postnatal periods, and bone age is typically advanced. Patients with DNA methyltransferase 3A mutations present similarly to Weaver syndrome, with typical facial features, tall stature, and intellectual disability.
Marfan syndrome, an autosomal dominant disorder of the fibrillin-1 gene, is characterized by tall stature, ectopia lentis, and aortic root dilation. While homocystinuria may have a presentation similar to that of Marfan syndrome, it is an autosomal recessive disorder of the cystathionine b-synthase gene. These patients are also predisposed to thromboembolic events, as well as psychiatric and learning disorders. Other syndromes associated with overgrowth include Beckwith-Wiedemann, Marshall-Smith, and Simpson-Golabi-Behmel. If a child with tall stature also has accompanying dysmorphic features, learning disorders, or behavioral concerns, he or she should be evaluated for a genetic cause of tall stature. An assessment of sitting height and arm span can be helpful, as eunuchoid proportions are consistent with Marfan syndrome, homocystinuria, Klinefelter syndrome, and hypogonadism, whereas Sotos and Weaver syndromes, by contrast, have proportional growth.
Overnutrition
Overnutrition that leads to obesity can increase linear growth in childhood, although adult height is not greater than expected. These patients can also manifest earlier-thanaverage puberty and advanced bone age. The mechanism regulating this pattern of growth is not fully understood. GH levels are typically low, but IGF-1 levels are normal. Ghrelin, leptin, GH secretagogue receptor, and hyperinsulinemic state all likely play a role in this complex system.
EVALUATION OF TALL STATURE
The evaluation of tall stature begins with a detailed history and physical examination. The patient's age and pubertal status, as well as the timing of the child's growth acceleration, are particularly important in guiding the differential diagnosis. The history should include a detailed family history (including the heights of the immediate and extended family members) and review of other associated symptoms and medical conditions. The physical examination should include a careful evaluation for dysmorphic features and disproportional growth. A routine diagnostic evaluation is less well defined, but initial laboratory evaluation may include assessment of GH signaling by measuring IGF-1 level, and radiologic evaluation may include a bone age assessment. Further diagnostic testing is guided by the history and physical examination findings, should a specific etiologic origin be suspected.
TREATMENT OF TALL STATURE
Treating the underlying cause of tall stature is the mainstay of management. Hyperthyroidism is treated with methimazole, an anti-thyroid medication. Central precocious puberty is treated with GnRH agonists, while congenital adrenal hyperplasia and adrenal insufficiency are treated with glucocorticoid replacement. GH excess can be treated medically, surgically, and with radiotherapy.
Treatment of tall stature with sex steroids is controversial. Testosterone therapy at doses ranging from 500 to 1,000 mg per month for 6 months to greater than 12 months has been used with consequent reduction in expected future growth by 50%. Lower doses administered for a shorter duration likely have similar effectiveness, although there are no prospective studies in which different treatment regimens have been compared. Side effects of high-dose testosterone include acne, edema, and gynecomastia. There have not been any identified long-term effects with therapy, relating to infertility or gonadal dysfunction. However, for girls treated with high-dose estrogen, fertility issues related to primary ovarian insufficiency have been identified. Highdose estrogen also causes weight gain, nausea, benign breast disease, excessive vaginal discharge, ovarian cysts, and thrombosis. Initiation of treatment should be carefully considered and weighed against potential risks, typically under the guidance of a subspecialist.
References and Suggested Readings for this article are at http://pedsinreview.aappublications.org/content/38/7/293.
Summary
• On the basis of strong research evidence, height is a heterogeneous trait with marked variation in the population and is largely attributable to genetic variability. (9) • On the basis of strong research evidence, growth velocity describes the pattern of growth over time, and, together with measurements of height and/or length, must be factored into clinical decision-making when evaluating children with abnormal growth and stature. (1)(2) • On the basis of some research evidence, as well as consensus, evaluation of short and tall stature includes a thorough history and physical examination, along with laboratory and radiologic examinations dictated by pertinent history, symptoms, and physical findings. Particularly for the evaluation of short stature, an initial set of screening laboratory studies should be performed.
(2)(3)
• On the basis of some research evidence, as well as consensus, timely referral to a pediatric endocrinologist is important when bone age is advanced and predicted adult height is compromised and in situations when growth hormone therapy may be indicated. (8) 
